In their review of new developments in pulmonary diseases affecting HIV infected individuals (March 1995; 50:294-302) Mitchell and Miller do not discuss bronchiectasis. They mention indolent bronchopulmonary Pseudomonas aeruginosa infection comparable to that seen in cystic fibrosis, but do not comment on bronchiectasis which is now well described in adults and children with HIV infection.
Bronchiectasis in a series of HIV infected adults was first reported from Oxford in 1992,' and the association has subsequently been confirmed in reports from the USA. 23 The incidence of bronchiectasis in the HIV infected population remains to be established; it is frequently undiagnosed because of a low index of suspicion and because chest radiographs may be normal or non-specific. High resolution computed tomographic (CT) scanning is the investigation of choice. The main conclusion of the paper by Drs Grove, McFarlane and Lipworth (February 1995; 50: 1348) that invivo salbutamol shows characteristics of a 13 adrenoceptor partial antagonist in a state of high adrenergic tone (exercise) is based upon the observation of similar effects of salbutamol and the nonselective 13 adrenoceptor antagonist, propranolol, in augmenting exercise-induced hyperkalaemia. The authors state that the mechanism of this augmentation of exerciseinduced hyperkalaemia is by P2 adrenoceptor antagonism since propranolol and the selective 02 adrenoceptor antagonist ICI 118 551 would show similar effects in this respect. It is the latter assumption that we would like to challenge. We think that it is more likely that the effect of salbutamol on the exercise-induced increase in potassium is due to some other yet unknown mechanism.
Concerning the effects of ICI 118 551 on exercise-induced hyperkalaemia, the authors refer to a paper on observations of the effects on plasma potassium levels in six healthy volunteers during a game of squash.' However, in that paper ICI 118 551 did not influence the exercise-induced increase in plasma potassium levels, as was also concluded by the authors of that paper. The difference in the mean plasma potassium level at the end of the exercise period between the placebo and active treatment groups can be explained by the difference in baseline potassium levels before exercise. Moreover, in another paper a direct comparison between propranolol and ICI 118551 of the effects on plasma potassium levels during exercise was made under standardised conditionsthat is, during incremental ergometer exercise.2 In that experiment only plasma potassium levels after pretreatment with propranolol were different from placebo, but plasma potassium levels after ICI 118 551 were identical to those after placebo pretreatment.
On the basis of these two studies, it is very unlikely that blockade of 12 adrenoceptors is involved in the phenomenon of exerciseinduced hyperkalaemia. Either non-specific 1 blockade or a non-1 adrenoceptor-mediated mechanism shared by several drugs of this class is involved. We think that the latter notion makes the conclusion of the paper by Grove et al concerning the 12 adrenoceptor partial antagonist activity of salbutamol at least subject to doubt. In the light of this, the implicit waming for the possible negative effects of salbutamol in the setting of acute asthma is unsubstantiated, particularly since this drug has been shown for many years to be of great clinical value in this potentially life threatening situation.
